Parkinson's disease severity and use of dopaminergic medications.
Parkinson's disease severity and use of dopaminergic medications.
复制标题
帕金森病的严重程度和多巴胺能药物的使用。
DOI：
10.1016/j.parkreldis.2014.10.016
复制
发表时间：
2015
影响因子：
4.1
通讯作者：
NINDSNET-PDInvestigators
中科院分区：
文献类型：
--
作者：
Fang,JohnY;Pérez,Adriana;Christine,ChadwickW;Leehey,Maureen;Aminoff,MichaelJ;Boyd,JamesT;Morgan,JohnC;Dhall,Rohit;Nicholas,AnthonyP;Bodis-Wollner,Ivan;Zweig,RichardM;Goudreau,JohnL;NINDSNET-PDInvestigators
BackgroundThe effects of dopaminergic therapy in parkinson's disease (PD) can vary depending on the class of medication selected.ObjectiveThe aim of thispost hocstudy was to determine if the class of dopaminergic therapy correlated with disease severity in persons with early, treated PD.MethodsA non-parametric global statistical test (GST) was used to assess the status of participants treated with dopamine agonist (DA) monotherapy, levodopa (LD) monotherapy or combined LD and DA therapy on multiple PD outcomes encompassing motor, cognitive, psychiatric and autonomic function, as well as disability and quality of life.ResultsThe outcomes measured at the beginning of the study showed lower disease burden for participants on initial DA monotherapy compared to those taking combined LD and DA therapy after controlling for age, education, taking cog-meds and amantadine.ConclusionThis observation suggests that clinicians treating early PD patients favor combined LD and DA therapy in patients with more disabling features over DA monotherapy. As such, studies of PD progression in treated PD patients may be affected by the class of symptomatic dopaminergic therapy.
一项比较普拉克索与左旋多巴治疗早期帕金森病的随机对照试验：CALM-PD 研究的设计和方法。
影响因子：
1
作者：
通讯作者：
--